Psoriasis Treatment Center of Central New Jersey
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.
Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of chronic plaque-type * Patient with 2-10% BSA * Physician Global Assessment of 2 or greater * Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks Exclusion Criteria: * ˂2 or \>10% BSA * PGA \<2 * Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.